Hanall Biopharma Co., Ltd. (KRX:009420)
28,700
+150 (0.53%)
At close: Mar 24, 2025, 3:30 PM KST
Hanall Biopharma Revenue
In the year 2024, Hanall Biopharma had annual revenue of 138.94B KRW with 2.99% growth. Hanall Biopharma had revenue of 36.42B in the quarter ending December 31, 2024, with 14.82% growth.
Revenue
138.94B
Revenue Growth
+2.99%
P/S Ratio
10.33
Revenue / Employee
449.66M
Employees
309
Market Cap
1,436.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
Dec 31, 2020 | 88.60B | -19.85B | -18.30% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,547.32B |
Celltrion | 3,557.30B |
ALTEOGEN | 102.85B |
Yuhan | 2,067.79B |
SK Biopharmaceuticals | 547.60B |
HLB Co., Ltd. | 51.92B |
Sam Chun Dang Pharm. | 210.92B |
PharmaResearch | 350.12B |